乳腺癌干細胞與基因分型_《中國普外基礎與臨床雜志》

作者：

韓明利 , 吳誠義

重慶醫科大學附屬第一醫院內分泌外科（重慶 400016）;

關鍵詞：

乳腺癌異質性基因分型腫瘤干細胞

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的總結乳腺癌干細胞與基因分型的研究進展,并分析二者之間的相關性。
方法分析近年來有關乳腺癌干細胞與基因分型研究的文獻報道。
結果乳腺癌干細胞與基因分型的相關性研究支持了乳腺癌的腫瘤干細胞起源學說,解釋了乳腺癌基因分型的復雜性及其異質性。
結論乳腺癌干細胞和基因分型的相關性研究能為從細胞分子水平研究乳腺癌的形成機理和生物學特性找到新的途徑,有望為乳腺癌的診斷和治療提供新的策略與手段。

引用本文： 韓明利,吳誠義. 乳腺癌干細胞與基因分型. 中國普外基礎與臨床雜志, 2010, 17(3): 302-305. doi: 復制

1.	魏于全,　吳揚. 乳腺癌生物治療進展 [J]. 中國普外基礎與臨床雜志, 2004; 11(1): 35.
2.	莫敖, 吳誠義. 腫瘤干細胞與實體腫瘤 [J]. 中國普外基礎與臨床雜志, 2007; 14(5): 612614.
3.	Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions [J]. Nat Rev Cancer, 2008; 8(10): 755768.
4.	AlHajj M, Wicha MS, BenitoHernandez A, et al. Prospective identification of tumorigenic breast cancer cells [J]. Proc Natl Acad Sci USA, 2003; 100(11): 39833988.
5.	Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties [J]. Cancer Res, 2005; 65(13): 55065511.
6.	Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis [J]. Breast Cancer Res, 2006; 8(5): R59.
7.	Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on [J]. Curr Stem Cell Res Ther, 2009; 4(1): 5060.
8.	Ginestier C, Hur MH, CharafeJauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome [J]. Cell Stem Cell, 2007; 1(5): 555567.
9.	Patrawala L, Calhoun T, SchneiderBroussard R, et al. Side population is enriched in tumorigenic, stemlike cancer cells, whereas ABCG2+ and ABCG2－ cancer cells are similarly tumorigenic [J]. Cancer Res, 2005; 65(14): 62076219.
10.	Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breastcancer cells [J]. N Engl J Med, 2007; 356(3): 217226.
11.	Phillips TM, McBride WH, Pajonk F. The response of CD24－/low/CD44+ breast cancer－initiating cells to radiation [J]. J Natl Cancer Inst, 2006; 98(24): 17771785.
12.	Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis [J]. Clin Cancer Res, 2005; 11(3): 11541159.
13.	Morimoto K, Kim SJ, Tanei T, et al. Stem cell marker aldehyde dehydrogenase 1positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression [J]. Cancer Sci, 2009; 100(6): 10621068.
14.	Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours [J]. Nature, 2000; 406(6797): 747752.
15.	Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/basallike breast carcinomas [J]. Breast Cancer Res, 2007; 9(5): R65.
16.	Lo SS, Norton J, Mumby PB, et al. Prospective multicenter study of the impact of the 21gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection [J]. J Clin Oncol, 2007; 25(18S): 577.
17.	Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy [J]. N Engl J Med, 2006; 354(20): 21032111.
18.	PiccartGebhart MJ, Procter M, LeylandJones B, et al. Trastuzumab after adjuvant chemotherapy in HER2positive breast cancer [J]. N Engl J Med, 2005; 353(16): 16591672.
19.	Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004; 10(16): 53675374.
20.	Srlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci USA, 2001; 98(19): 1086910874.
21.	Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse [J]. Cancer Res, 2008; 68(9): 31083114.
22.	Honeth G, Bendahl PO, Ringnér M, et al. The CD44+/CD24- phenotype is enriched in basallike breast tumors [J]. Breast Cancer Res, 2008; 10(3): R53.
23.	Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes [J]. Cancer Cell, 2006; 10(6): 515527.
24.	Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells [J]. Cell, 2008; 133(4): 704715.
25.	Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity [J]. Cancer Cell, 2007; 11(3): 259273.
26.	Korkaya H, Paulson A, Iovino F, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion [J]. Oncogene, 2008; 27(47): 61206130.
27.	Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1 [J]. Cancer Res, 2008; 68(7): 24192426.
28.	Zhang M, Behbod F, Atkinson RL, et al. Identification of tumorinitiating cells in a p53null mouse model of breast cancer [J]. Cancer Res, 2008; 68(12): 46744682.
29.	Molyneux G, Regan J, Smalley MJ. Mammary stem cells and breast cancer [J]. Cell Mol Life Sci, 2007; 64(24): 32483260.
30.	Dontu G, ElAshry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor [J]. Trends Endocrinol Metab, 2004; 15(5): 193197.

1. 魏于全,　吳揚. 乳腺癌生物治療進展 [J]. 中國普外基礎與臨床雜志, 2004; 11(1): 35.
2. 莫敖, 吳誠義. 腫瘤干細胞與實體腫瘤 [J]. 中國普外基礎與臨床雜志, 2007; 14(5): 612614.
3. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions [J]. Nat Rev Cancer, 2008; 8(10): 755768.
4. AlHajj M, Wicha MS, BenitoHernandez A, et al. Prospective identification of tumorigenic breast cancer cells [J]. Proc Natl Acad Sci USA, 2003; 100(11): 39833988.
5. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties [J]. Cancer Res, 2005; 65(13): 55065511.
6. Sheridan C, Kishimoto H, Fuchs RK, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis [J]. Breast Cancer Res, 2006; 8(5): R59.
7. Nakshatri H, Srour EF, Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on [J]. Curr Stem Cell Res Ther, 2009; 4(1): 5060.
8. Ginestier C, Hur MH, CharafeJauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome [J]. Cell Stem Cell, 2007; 1(5): 555567.
9. Patrawala L, Calhoun T, SchneiderBroussard R, et al. Side population is enriched in tumorigenic, stemlike cancer cells, whereas ABCG2+ and ABCG2－ cancer cells are similarly tumorigenic [J]. Cancer Res, 2005; 65(14): 62076219.
10. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breastcancer cells [J]. N Engl J Med, 2007; 356(3): 217226.
11. Phillips TM, McBride WH, Pajonk F. The response of CD24－/low/CD44+ breast cancer－initiating cells to radiation [J]. J Natl Cancer Inst, 2006; 98(24): 17771785.
12. Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis [J]. Clin Cancer Res, 2005; 11(3): 11541159.
13. Morimoto K, Kim SJ, Tanei T, et al. Stem cell marker aldehyde dehydrogenase 1positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression [J]. Cancer Sci, 2009; 100(6): 10621068.
14. Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumours [J]. Nature, 2000; 406(6797): 747752.
15. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological characterization of triplenegative/basallike breast carcinomas [J]. Breast Cancer Res, 2007; 9(5): R65.
16. Lo SS, Norton J, Mumby PB, et al. Prospective multicenter study of the impact of the 21gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection [J]. J Clin Oncol, 2007; 25(18S): 577.
17. Pritchard KI, Shepherd LE, O’Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy [J]. N Engl J Med, 2006; 354(20): 21032111.
18. PiccartGebhart MJ, Procter M, LeylandJones B, et al. Trastuzumab after adjuvant chemotherapy in HER2positive breast cancer [J]. N Engl J Med, 2005; 353(16): 16591672.
19. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004; 10(16): 53675374.
20. Srlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J]. Proc Natl Acad Sci USA, 2001; 98(19): 1086910874.
21. Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse [J]. Cancer Res, 2008; 68(9): 31083114.
22. Honeth G, Bendahl PO, Ringnér M, et al. The CD44+/CD24- phenotype is enriched in basallike breast tumors [J]. Breast Cancer Res, 2008; 10(3): R53.
23. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes [J]. Cancer Cell, 2006; 10(6): 515527.
24. Mani SA, Guo W, Liao MJ, et al. The epithelialmesenchymal transition generates cells with properties of stem cells [J]. Cell, 2008; 133(4): 704715.
25. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity [J]. Cancer Cell, 2007; 11(3): 259273.
26. Korkaya H, Paulson A, Iovino F, et al. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion [J]. Oncogene, 2008; 27(47): 61206130.
27. Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1 [J]. Cancer Res, 2008; 68(7): 24192426.
28. Zhang M, Behbod F, Atkinson RL, et al. Identification of tumorinitiating cells in a p53null mouse model of breast cancer [J]. Cancer Res, 2008; 68(12): 46744682.
29. Molyneux G, Regan J, Smalley MJ. Mammary stem cells and breast cancer [J]. Cell Mol Life Sci, 2007; 64(24): 32483260.
30. Dontu G, ElAshry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor [J]. Trends Endocrinol Metab, 2004; 15(5): 193197.

《中國普外基礎與臨床雜志》

乳腺癌干細胞與基因分型

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

乳腺癌干細胞與基因分型

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料